Teva Pharmaceutical Industries agreed to collaborate with Nuvelution Pharma in advancing the development of Austedo, or deutetrabenazine, as a treatment for patients with Tourette's syndrome. Teva will be responsible for the regulatory process and commercialization of Austedo, which is expected to be under a late-stage study in fourth quarter of the year, while Nuvelution will fund the clinical trials.
An agreement was reached by Centinel Spine to buy the Prodisc-C, Prodisc-L, Prodisc-C Nova, Prodisc-C Vivo, Prodisc-O and Discover cervical and lumbar artificial disc systems from Johnson & Johnson subsidiary DePuy Synthes for undisclosed terms. The transaction is expected to be completed in the fourth quarter.
The attorneys general of 41 states collectively issued subpoenas to manufacturers and distributors of opioid drugs, seeking information on marketing to health care professionals and patients. The AGs seek "to uncover whether or not there was deception involved, if manufacturers misled doctors and patients about the efficacy and addictive power of these drugs," said New York Attorney General Eric Schneiderman.
The market for biologic and biosimilar drugs is full of both opportunities and uncertainties regarding competition, adoption and pricing, according to Yogesh Soneji of Trinity Partners. Companies will compete in both the branded biologics and biosimilars spaces, he said, and biosimilars will eventually drive down prices.
The FDA will publicly release letters the agency sends when generic-drug makers ask the FDA for permission to obtain samples of brand-name drugs for bioequivalence testing. The policy is part of a push to prevent drugmakers from using Risk Evaluation and Mitigation Strategies to withhold samples and prevent generic competition.
Despite a strengthening economy and high job rates, most US workers are unlikely to see sizable increases in their salaries for 2018, according to Aon's 2017 US Salary Increase Survey of 1,062 US companies. It expects base pay to be 3% in 2018, up slightly from 2.9% in 2017. Read more.
"After hundreds of years of paper notes and cashiers in our banks, I predict that we will be cashless and digital within the next 30 years," says John Brosnan, head of Financial Services Group, Aon Risk Solutions. The Financial Times has described cash as a "barbarous relic" and around the world; digital cryptocurrencies compete to provide people with what is designed to be a completely decentralized currency. Understanding why people are looking to stop circulating cash and what the advantages and pitfalls could be is becoming increasingly important. Read more.
Going to bed at night saying we've done something wonderful ... that's what matters to me.
Aon provides Life Sciences companies with end-to-end risk solutions, supporting organizations from the initial discovery phase to final product launch. The practice provides solutions across the Life Sciences for pharmaceutical manufacturers; generic and OTC pharmaceutical companies; biotechnology and biopharmaceutical companies; genomic and proteomic companies; drug delivery system; diagnostic substance companies; and medical device and equipment manufacturers.
Aon plc (NYSE:AON) is a leading global professional services firm providing a broad range of risk, retirement and health solutions. Our 50,000 colleagues in 120 countries empower results for clients by using proprietary data and analytics to deliver insights that reduce volatility and improve performance.